In the midst of a global COVID-19 pandemic, a top priority for many pharma and biopharma companies is to get a vaccine developed, produced, and delivered to the public as quickly as possible. Ushering a vaccine through rigorous testing protocols and regulatory approvals is not an easy (or quick) effort, but incorporating advanced data analytics could help accelerate the process. Data analytics has proven effective in speeding vaccine development both by enabling more efficient Design of Experiments (DOE) and by creating rapid-scale production rollout processes. Tomasz Adamusiak, Director of Data Science at Pfizer sits down with TDS to explain what his company, Pfizer, is doing with the vaccine as well as what a designed vaccine is.

Tomasz Adamusiak
https://www.linkedin.com/in/adamusiak/

The Data Standard
https://datastandard.io/
https://www.linkedin.com/company/the-data-standard/